Literature DB >> 27851923

HIV Broadly Neutralizing Antibodies: Taking Good Care Of The 98.

Devin Sok1, Dennis R Burton2.   

Abstract

In this issue of Immunity, Huang et al. (2016) describe an exceptionally broad and potent neutralizing antibody to HIV. This antibody, N6, is capable of neutralizing up to 98% of global isolates with a potent median IC50 of 0.04 μg/mL, making it the current "best-in-class" for bNAbs targeting the CD4 binding site.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27851923      PMCID： PMC5378060          DOI： 10.1016/j.immuni.2016.10.033

Source DB:  PubMed          Journal:  Immunity        ISSN： 1074-7613            Impact factor:   31.745


  9 in total

Review 1.  Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design.

Authors:  Dennis R Burton; Lars Hangartner
Journal:  Annu Rev Immunol       Date:  2016-05-20       Impact factor: 28.527

2.  Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex.

Authors:  Devin Sok; Marit J van Gils; Matthias Pauthner; Jean-Philippe Julien; Karen L Saye-Francisco; Jessica Hsueh; Bryan Briney; Jeong Hyun Lee; Khoa M Le; Peter S Lee; Yuanzi Hua; Michael S Seaman; John P Moore; Andrew B Ward; Ian A Wilson; Rogier W Sanders; Dennis R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-24       Impact factor: 11.205

3.  Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.

Authors:  Marina Caskey; Florian Klein; Julio C C Lorenzi; Michael S Seaman; Anthony P West; Noreen Buckley; Gisela Kremer; Lilian Nogueira; Malte Braunschweig; Johannes F Scheid; Joshua A Horwitz; Irina Shimeliovich; Sivan Ben-Avraham; Maggi Witmer-Pack; Martin Platten; Clara Lehmann; Leah A Burke; Thomas Hawthorne; Robert J Gorelick; Bruce D Walker; Tibor Keler; Roy M Gulick; Gerd Fätkenheuer; Sarah J Schlesinger; Michel C Nussenzweig
Journal:  Nature       Date:  2015-04-08       Impact factor: 49.962

4.  Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.

Authors:  Xueling Wu; Zhi-Yong Yang; Yuxing Li; Carl-Magnus Hogerkorp; William R Schief; Michael S Seaman; Tongqing Zhou; Stephen D Schmidt; Lan Wu; Ling Xu; Nancy S Longo; Krisha McKee; Sijy O'Dell; Mark K Louder; Diane L Wycuff; Yu Feng; Martha Nason; Nicole Doria-Rose; Mark Connors; Peter D Kwong; Mario Roederer; Richard T Wyatt; Gary J Nabel; John R Mascola
Journal:  Science       Date:  2010-07-08       Impact factor: 47.728

Review 5.  Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life.

Authors:  Austin W Boesch; Galit Alter; Margaret E Ackerman
Journal:  Curr Opin HIV AIDS       Date:  2015-05       Impact factor: 4.283

6.  Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.

Authors:  D R Burton; J Pyati; R Koduri; S J Sharp; G B Thornton; P W Parren; L S Sawyer; R M Hendry; N Dunlop; P L Nara
Journal:  Science       Date:  1994-11-11       Impact factor: 47.728

7.  Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults.

Authors:  J E Ledgerwood; E E Coates; G Yamshchikov; J G Saunders; L Holman; M E Enama; A DeZure; R M Lynch; I Gordon; S Plummer; C S Hendel; A Pegu; M Conan-Cibotti; S Sitar; R T Bailer; S Narpala; A McDermott; M Louder; S O'Dell; S Mohan; J P Pandey; R M Schwartz; Z Hu; R A Koup; E Capparelli; J R Mascola; B S Graham
Journal:  Clin Exp Immunol       Date:  2015-09-24       Impact factor: 4.330

8.  Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors.

Authors:  Tongqing Zhou; Rebecca M Lynch; Lei Chen; Priyamvada Acharya; Xueling Wu; Nicole A Doria-Rose; M Gordon Joyce; Daniel Lingwood; Cinque Soto; Robert T Bailer; Michael J Ernandes; Rui Kong; Nancy S Longo; Mark K Louder; Krisha McKee; Sijy O'Dell; Stephen D Schmidt; Lillian Tran; Zhongjia Yang; Aliaksandr Druz; Timothy S Luongo; Stephanie Moquin; Sanjay Srivatsan; Yongping Yang; Baoshan Zhang; Anqi Zheng; Marie Pancera; Tatsiana Kirys; Ivelin S Georgiev; Tatyana Gindin; Hung-Pin Peng; An-Suei Yang; James C Mullikin; Matthew D Gray; Leonidas Stamatatos; Dennis R Burton; Wayne C Koff; Myron S Cohen; Barton F Haynes; Joseph P Casazza; Mark Connors; Davide Corti; Antonio Lanzavecchia; Quentin J Sattentau; Robin A Weiss; Anthony P West; Pamela J Bjorkman; Johannes F Scheid; Michel C Nussenzweig; Lawrence Shapiro; John R Mascola; Peter D Kwong
Journal:  Cell       Date:  2015-05-21       Impact factor: 41.582

9.  Broad neutralization coverage of HIV by multiple highly potent antibodies.

Authors:  Laura M Walker; Michael Huber; Katie J Doores; Emilia Falkowska; Robert Pejchal; Jean-Philippe Julien; Sheng-Kai Wang; Alejandra Ramos; Po-Ying Chan-Hui; Matthew Moyle; Jennifer L Mitcham; Phillip W Hammond; Ole A Olsen; Pham Phung; Steven Fling; Chi-Huey Wong; Sanjay Phogat; Terri Wrin; Melissa D Simek; Wayne C Koff; Ian A Wilson; Dennis R Burton; Pascal Poignard
Journal:  Nature       Date:  2011-09-22       Impact factor: 49.962
  9 in total
  6 in total

1.  In vivo engineered B cells secrete high titers of broadly neutralizing anti-HIV antibodies in mice.

Authors:  Alessio D Nahmad; Cicera R Lazzarotto; Natalie Zelikson; Talia Kustin; Mary Tenuta; Deli Huang; Inbal Reuveni; Daniel Nataf; Yuval Raviv; Miriam Horovitz-Fried; Iris Dotan; Yaron Carmi; Rina Rosin-Arbesfeld; David Nemazee; James E Voss; Adi Stern; Shengdar Q Tsai; Adi Barzel
Journal:  Nat Biotechnol       Date:  2022-06-09       Impact factor: 68.164

2.  Geospatial HIV-1 subtype C gp120 sequence diversity and its predicted impact on broadly neutralizing antibody sensitivity.

Authors:  Jyoti Sutar; Suprit Deshpande; Ranajoy Mullick; Nitin Hingankar; Vainav Patel; Jayanta Bhattacharya
Journal:  PLoS One       Date:  2021-05-24       Impact factor: 3.240

3.  HIV-Specific B Cell Frequency Correlates with Neutralization Breadth in Patients Naturally Controlling HIV-Infection.

Authors:  Angeline Rouers; Jéromine Klingler; Bin Su; Assia Samri; Géraldine Laumond; Sophie Even; Véronique Avettand-Fenoel; Clemence Richetta; Nicodème Paul; Faroudy Boufassa; Laurent Hocqueloux; Hugo Mouquet; Christine Rouzioux; Olivier Lambotte; Brigitte Autran; Stéphanie Graff-Dubois; Christiane Moog; Arnaud Moris
Journal:  EBioMedicine       Date:  2017-05-31       Impact factor: 8.143

Review 4.  When designing vaccines, consider the starting material: the human B cell repertoire.

Authors:  Colin Havenar-Daughton; Robert K Abbott; William R Schief; Shane Crotty
Journal:  Curr Opin Immunol       Date:  2018-09-03       Impact factor: 7.486

Review 5.  Vaccine Evolution and Its Application to Fight Modern Threats.

Authors:  Emanuele Andreano; Ugo D'Oro; Rino Rappuoli; Oretta Finco
Journal:  Front Immunol       Date:  2019-07-25       Impact factor: 7.561

6.  Characterization of a vaccine-elicited human antibody with sequence homology to VRC01-class antibodies that binds the C1C2 gp120 domain.

Authors:  Matthew D Gray; Junli Feng; Connor E Weidle; Kristen W Cohen; Lamar Ballweber-Fleming; Anna J MacCamy; Crystal N Huynh; Josephine J Trichka; David Montefiori; Guido Ferrari; Marie Pancera; M Juliana McElrath; Leonidas Stamatatos
Journal:  Sci Adv       Date:  2022-05-04       Impact factor: 14.957
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.